CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Cetuximab +1 moredrug
Likely dose
Cetuximab 400 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03446157
NCT03446157Phase 2Completed
CompareCT.gov

Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer

UNC Lineberger Comprehensive Cancer Center·interventional·Posted Feb 26, 2018·Updated Mar 10, 2026

In Brief

A Phase 2 clinical trial evaluating Cetuximab and Palbociclib for Cancer of the Colon and 4 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer, Neoplasms, Colonic
CountriesUnited States
CollaboratorsAmgen, Pfizer

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 26, 2018
Enrollment StartMar 23, 2018
Primary CompletionMay 29, 2023
Study CompletionJan 26, 2026
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 8.3 years ago

Interventions

Cetuximabdrug

Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib

Palbociclibdrug

125 mg taken orally once daily on days 1-21, then 7 days off